Literature DB >> 29104811

Bile acid metabolism and signaling in liver disease and therapy.

John Y L Chiang1.   

Abstract

Bile acids play a critical role in the regulation of glucose, lipid, and energy metabolism through activation of the nuclear bile acid receptor farnesoid X receptor (FXR) and membrane G protein-coupled bile acid receptor-1 (Gpbar-1, aka TGR5). Agonist activation of FXR and TGR5 improves insulin and glucose sensitivity and stimulates energy metabolism to prevent diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Bile acids have both pro- and anti-inflammatory actions through FXR and TGR5 in the intestine and liver. In the intestine, bile acids activate FXR and TGR5 to stimulate stimulate fibroblast growth factor 15 and glucagon-like peptide-1 secretion. FXR and TGR5 agonists may have therapeutic potential for treating liver-related metabolic diseases, such as diabetes and NAFLD.

Entities:  

Keywords:  Bile acid metabolism; Cholestatic liver; diseases Metabolic diseases

Year:  2017        PMID: 29104811      PMCID: PMC5663306          DOI: 10.1016/j.livres.2017.05.001

Source DB:  PubMed          Journal:  Liver Res


  92 in total

Review 1.  Oxysterols: friends, foes, or just fellow passengers?

Authors:  Ingemar Björkhem; Ulf Diczfalusy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-05-01       Impact factor: 8.311

2.  Bile acid is a host factor that regulates the composition of the cecal microbiota in rats.

Authors:  K B M Saiful Islam; Satoru Fukiya; Masahito Hagio; Nobuyuki Fujii; Satoshi Ishizuka; Tadasuke Ooka; Yoshitoshi Ogura; Tetsuya Hayashi; Atsushi Yokota
Journal:  Gastroenterology       Date:  2011-08-10       Impact factor: 22.682

3.  Assessment of biliary bicarbonate secretion in humans by positron emission tomography.

Authors:  J Prieto; N García; J M Martí-Climent; I Peñuelas; J A Richter; J F Medina
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

Review 4.  Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.

Authors:  Luciano Adorini; Mark Pruzanski; David Shapiro
Journal:  Drug Discov Today       Date:  2012-05-29       Impact factor: 7.851

5.  Glucose stimulates cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes.

Authors:  Tiangang Li; Dipanjan Chanda; Yanqiao Zhang; Hueng-Sik Choi; John Y L Chiang
Journal:  J Lipid Res       Date:  2009-10-28       Impact factor: 5.922

6.  The TGR5 receptor mediates bile acid-induced itch and analgesia.

Authors:  Farzad Alemi; Edwin Kwon; Daniel P Poole; TinaMarie Lieu; Victoria Lyo; Fiore Cattaruzza; Ferda Cevikbas; Martin Steinhoff; Romina Nassini; Serena Materazzi; Raquel Guerrero-Alba; Eduardo Valdez-Morales; Graeme S Cottrell; Kristina Schoonjans; Pierangelo Geppetti; Stephen J Vanner; Nigel W Bunnett; Carlos U Corvera
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

7.  Expression and function of the bile acid receptor TGR5 in Kupffer cells.

Authors:  Verena Keitel; Markus Donner; Stefanie Winandy; Ralf Kubitz; Dieter Häussinger
Journal:  Biochem Biophys Res Commun       Date:  2008-05-09       Impact factor: 3.575

8.  Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.

Authors:  Hiroyuki Sato; Antonio Macchiarulo; Charles Thomas; Antimo Gioiello; Mizuho Une; Alan F Hofmann; Régis Saladin; Kristina Schoonjans; Roberto Pellicciari; Johan Auwerx
Journal:  J Med Chem       Date:  2008-02-29       Impact factor: 7.446

9.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

10.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Authors:  Gideon M Hirschfield; Andrew Mason; Velimir Luketic; Keith Lindor; Stuart C Gordon; Marlyn Mayo; Kris V Kowdley; Catherine Vincent; Henry C Bodhenheimer; Albert Parés; Michael Trauner; Hanns-Ulrich Marschall; Luciano Adorini; Cathi Sciacca; Tessa Beecher-Jones; Erin Castelloe; Olaf Böhm; David Shapiro
Journal:  Gastroenterology       Date:  2014-12-11       Impact factor: 22.682

View more
  59 in total

Review 1.  Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.

Authors:  John Y L Chiang; Jessica M Ferrell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-27       Impact factor: 4.052

2.  The 'in vivo lifestyle' of bile acid 7α-dehydroxylating bacteria: comparative genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial community in gnotobiotic mice.

Authors:  Jason M Ridlon; Saravanan Devendran; João Mp Alves; Heidi Doden; Patricia G Wolf; Gabriel V Pereira; Lindsey Ly; Alyssa Volland; Hajime Takei; Hiroshi Nittono; Tsuyoshi Murai; Takao Kurosawa; George E Chlipala; Stefan J Green; Alvaro G Hernandez; Christopher J Fields; Christy L Wright; Genta Kakiyama; Isaac Cann; Purna Kashyap; Vance McCracken; H Rex Gaskins
Journal:  Gut Microbes       Date:  2019-06-09

3.  Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models.

Authors:  Prasant Kumar Jena; Lili Sheng; Nidhi Nagar; Chao Wu; Daniela Barile; David A Mills; Yui-Jui Yvonne Wan
Journal:  J Nutr Biochem       Date:  2018-04-25       Impact factor: 6.048

4.  Long Non-coding RNA in Liver Metabolism and Disease: Current Status.

Authors:  Yulan Zhao; Jianguo Wu; Suthat Liangpunsakul; Li Wang
Journal:  Liver Res       Date:  2017-12-02

5.  Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection.

Authors:  Susanna Naggie; Sam Lusk; J Will Thompson; Meredith Mock; Cynthia Moylan; Joseph E Lucas; Laura Dubois; Lisa St John-Williams; M Arthur Moseley; Keyur Patel
Journal:  J Infect Dis       Date:  2020-11-13       Impact factor: 5.226

6.  Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury.

Authors:  Li Ren; Qing Song; Yunhuan Liu; Lihua Zhang; Zhiming Hao; Wenke Feng
Journal:  Biochem Biophys Res Commun       Date:  2019-09-28       Impact factor: 3.575

7.  A Mitochondrial VDAC1-Based Peptide Greatly Suppresses Steatosis and NASH-Associated Pathologies in a Mouse Model.

Authors:  Srinivas Pittala; Yakov Krelin; Yael Kuperman; Varda Shoshan-Barmatz
Journal:  Mol Ther       Date:  2019-07-12       Impact factor: 11.454

8.  Liver metabolomics in a mouse model of erythropoietic protoporphyria.

Authors:  Pengcheng Wang; Madhav Sachar; Grace L Guo; Amina I Shehu; Jie Lu; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2018-06-12       Impact factor: 5.858

9.  Ile258Met mutation of Brucella melitensis 7α-hydroxysteroid dehydrogenase significantly enhances catalytic efficiency, cofactor affinity, and thermostability.

Authors:  Zhiyong Liu; Rongzhen Zhang; Wenchi Zhang; Yan Xu
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-03       Impact factor: 4.813

Review 10.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.